Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.

Saved in:
Bibliographic Details
Title: Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
Authors: Gondry O; Department of Medical Imaging, Vrije Universiteit Brussel, Brussels, Belgium; odrade.gondry@uzbrussel.be marleen.keyaerts@vub.be.; Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium., Caveliers V; Department of Medical Imaging, Vrije Universiteit Brussel, Brussels, Belgium.; Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium., Xavier C; Department of Medical Imaging, Vrije Universiteit Brussel, Brussels, Belgium., Raes L; Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium., Vanhoeij M; Department of Surgical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Verfaillie G; Department of Surgical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Fontaine C; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Glorieus K; Department of Surgical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium., De Grève J; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Joris S; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Luyten I; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Zwaenepoel K; Centre for Oncological Research, University of Antwerp, Wilrijk, Belgium., Vandenbroucke F; Department of Radiology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Waelput W; Department of Pathology, Universitair Ziekenhuis Brussel, Brussels, Belgium.; Experimental Pathology, Vrije Universiteit Brussel, Brussels, Belgium., Thyparambil S; mProbe, Rockville, Maryland; and., Vaneycken I; Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium., Cousaert J; Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium., Bourgeois S; Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium., Devoogdt N; Department of Medical Imaging, Vrije Universiteit Brussel, Brussels, Belgium., Goethals L; Department of Radiology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Everaert H; Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium., De Geeter F; Department of Nuclear Medicine, Algemeen Ziekenhuis Sint-Jan Brugge Oostende, Bruges, Belgium., Lahoutte T; Department of Medical Imaging, Vrije Universiteit Brussel, Brussels, Belgium.; Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium., Keyaerts M; Department of Medical Imaging, Vrije Universiteit Brussel, Brussels, Belgium; odrade.gondry@uzbrussel.be marleen.keyaerts@vub.be.; Department of Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Source: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Feb 01; Vol. 65 (2), pp. 178-184. Date of Electronic Publication: 2024 Feb 01.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1535-5667
DOI:10.2967/jnumed.123.266254